Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Informatics » FDA, CancerLinQ to Track Real-World Targeted Therapy Use, Starting With Melanoma Drugs

FDA, CancerLinQ to Track Real-World Targeted Therapy Use, Starting With Melanoma Drugs

Jun 05, 2017
|
Molika Ashford

CHICAGO (GenomeWeb) – The American Society for Clinical Oncology announced this week that it has added two new long-term partners to its big-data initiative CancerLinQ, one of which is the US Food and Drug Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Suit and Settlement

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

CRUK Announces Cuts

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Long Wait

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

PNAS Papers on Ancient European Migrations, Triple-Negative Breast Cancer Fusions, More

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Informatics

  1. Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery

  2. Colorado Center for Personalized Medicine Ramps Up PGx Decision Support Efforts

    Premium

  3. Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.